{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-024718","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.831144+00:00","generated_at":"2026-05-31T12:04:09.792738+00:00","sec_items":["1.01","1.02","2.2","2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TG Therapeutics Q2 BRIUMVI rev $72.6M, raises guidance; $250M credit facility; material weakness","bullets":["Q2 BRIUMVI net revenue $72.6M (+350% YoY); net income $6.9M vs loss $47.6M.","Raises FY 2024 BRIUMVI revenue target to ~$290-300M, up from $270-290M.","New $250M term loan repays $107M Hercules debt; $100M share repurchase authorized.","Material weakness in ICFR from 2021 restricted stock grant error; immaterial to financials; 10-K/A to be filed.","Phase 1 subcutaneous ublituximab in RMS initiated; FDA IND clearance for azer-cel in progressive MS."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-024718","json":"https://secwatch.observer/filing/0001437749-24-024718.json","markdown":"https://secwatch.observer/filing/0001437749-24-024718.md","text":"https://secwatch.observer/filing/0001437749-24-024718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924024718/0001437749-24-024718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924024718/tgtx20240805_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:04:09.792738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}